Press Releases

Date Title and Summary View
Toggle Summary Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conference being held from May 23-26, 2022 and at
View HTML
Toggle Summary Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) --   Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2022.
View HTML
Toggle Summary Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., April 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.  (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its first data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase
View HTML
Toggle Summary Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2021.
View HTML
Toggle Summary Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022.
View HTML
Toggle Summary Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021,
View HTML
Toggle Summary Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to advise on path forward
View HTML
Toggle Summary Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update
Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning and operational direction in the development of belapectin in cancer immunotherapy Management team
View HTML
Toggle Summary UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
New data regarding the mechanism of action of belapectin to inhibit galectin-3 Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiency Innovating in Liver Cirrhosis: Belapectin’s NAVIGATE phase 2b/3 study design New data regarding correlation between routine liver tests
View HTML
Toggle Summary UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021.
View HTML